(Q37971161)

26 August 2017

title

Treatment of MRSA soft tissue infections: an overview (English)

1 reference

26 August 2017

M Morgan

1

1 reference

26 August 2017

publication date

1 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

42 Suppl 5

1 reference

26 August 2017

page(s)

S11-7

1 reference

Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

The growing menace of community-acquired methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Community-acquired methicillin-resistant staphylococcus aureus: an emerging problem in the athletic population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Multiple cases of familial transmission of community-acquired methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Diagnosis and treatment of Panton-Valentine leukocidin (PVL)-associated staphylococcal pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Community-acquired MRSA bacteremic necrotizing pneumonia in a patient with scrotal ulceration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Purpura fulminans due to Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

7 January 2021

STAPHYLOCOCCAL TOXIN.

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 clone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Nottingham Staphylococcus aureus population study: prevalence of MRSA among elderly people in the community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

The emergence of meticillin-resistant Staphylococcus aureus among injecting drug users.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Staphylococcus aureus isolates carrying Panton-Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Panton-Valentine leukocidin associated staphylococcal disease: a cross-sectional study at a London hospital, England.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Outcomes of community-acquired, methicillin-resistant Staphylococcus aureus, soft tissue infections treated with antibiotics other than vancomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Is the recent emergence of community-associated methicillin-resistant Staphylococcus aureus among participants in competitive sports limited to participants?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Cutaneous community-acquired methicillin-resistant Staphylococcus aureus infection in participants of athletic activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Antimicrobial susceptibilities of health care-associated and community-associated strains of methicillin-resistant Staphylococcus aureus from hospitalized patients in Canada, 1995 to 2008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Methicillin-resistant Staphylococcus aureus disease in three communities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Three-year surveillance of community-acquired Staphylococcus aureus infections in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Uptake and intracellular activity of linezolid in human phagocytes and nonphagocytic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Managing skin and soft tissue infections: expert panel recommendations on key decision points

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Doxycycline for community-associated methicillin-resistant Staphylococcus aureus skin and soft-tissue infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Antimicrobial activities of trimethoprim/sulfamethoxazole, 5-iodo-2′-deoxyuridine and rifampicin against Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Severe osteoarticular infection associated with Panton-Valentine leukocidin-producing Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Are antibiotics necessary after incision and drainage of a cutaneous abscess?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Pyomyositis caused by methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Meeting the challenges of methicillin-resistant Staphylococcus aureus with outpatient parenteral antimicrobial therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Diagnosis and management of necrotising fasciitis: a multiparametric approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Disseminated sepsis due to a Panton-Valentine leukocidin producing strain of community acquired meticillin resistant Staphylococcus aureus and use of intravenous immunoglobulin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Antibiotic-induced persistence of cytotoxic Staphylococcus aureus in non-phagocytic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Trimethoprim-sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Community-acquired methicillin-resistant Staphylococcus aureus emerging as an important cause of necrotizing fasciitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Management of skin and soft-tissue infections in the emergency department

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Community-associated methicillin-resistant Staphylococcus aureus, Colombia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Incidence and clinical characteristics of methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a large urban hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Community-associated methicillin-resistant Staphylococcus aureus necrotizing fasciitis in a neonate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Neonatal necrotizing fasciitis due to community-acquired methicillin resistant Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Future treatment options for Gram-positive infections--looking ahead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-1383%2811%2970127-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0020-1383(11)70127-9

1 reference

release_h36m6dx64fad7og3wpautpnbcy

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h36m6dx64fad7og3wpautpnbcy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference